Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

meRfi® AI Chat

Enasidenib & Acute myeloid leukemia (AML) (IDH1 m)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

Approval status

Enasidenib (Idhifa TM) was approved by the FDA on August 1, 2017 for adult patients with relapsed or refractory Acute myeloid leukemia (AML) (IDH1 m). Detected by the FDA-approved Abbott RealTime IDH2 assay. No EMA approval for enasidenib in AML; only holds historical orphan designation without EU marketing authorization (1, 2, 3)

References

(1) Heymach et al. 2018
(2) fda-approves-new-targeted-treatment-relapsed-or-refractory-acute-myeloid-leukemia
(3)…

References (Sources)

Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology
Heymach et al. 2018
Enasidenib for the treatment of acute myeloid leukemia
Dugan & Pollyea 2018 Expert Rev Clin Pharmacol 11(8): 755-760
Review
Enasidenib, a targeted inhibitor of mutant IDH2 proteins for treatment of relapsed or refractory acute myeloid leukemia
Stein 2018 Future Oncol. 14(1): 23-40

AI Chat

7/1/2026

Chat with our artificial intelligence:

Start chat!